Cytochrome P4502D6 genotype does not determine response to clozapine.

British Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1995, Pages 417-420

  Arranz, MJ ^a   Dawson, E ^a   Shaikh, S ^a   Sham, P ^a   Sharma, T ^a   Aitchison, K ^a   Crocq, MA ^a   Gill, M ^a   Kerwin, R ^a   Collier, DA ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ALLELES; CLOZAPINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; MIXED FUNCTION OXYGENASES; MUTATION; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; SCHIZOPHRENIA; SUPPORT, NON-U.S. GOV'T;

EID: 0028902662     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1995.tb04471.x     Document Type: Article

References (29)

1. The new atypical antipsychotics
2. 2‐dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
3. Clinical studies on the mechanism of action of clozapine: the dopamine‐serotonin hypothesis of schizophrenia
4. 4 receptor with high affinity for the antipsychotic clozapine
5. Dopamine D4 receptor subtypes and response to clozapine
6. Serotonin function and treatment response to clozapine in schizophrenic patients
7. Multiple dopamine D4 receptor subtypes in the human population
8. 3‐ groups in metabolizing clozapine in the human organism
9. The metabolism of 8‐chloro‐11‐(4‐methyl‐l‐piperazinyl)‐5H‐dibenzo[b, e]diazepine (clozapine) in mice, dogs and human subjects
10. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6
11. Disposition of clozapine in man: Lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms
12. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service
13. Human cytochromes P450: problems and prospects
14. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S‐mephenytoin
15. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans
16. Clinical pharmacogenetics of clomipramine
17. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
18. The human debrisoquine 4‐hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene
19. The human CYP2D locus associated with a common genetic defect in drug oxidation. A base change in Intron 3 of a mutant CYP2D6 allele results in an aberrant splice recognition site
20. Identification of the primary gene defect at the cytochrome P450 CYP2D locus
21. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired dug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism
22. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
23. The Global Assessment Scale
24. Debrisoquine‐4‐hydroxylase (CYP2D6) locus and possible susceptibility to schizophrenia
25. Extremely rapid hydroxylation of debrisoquine: a case report with implications for treatment with nortryptiline and other tricyclic antidepressants
26. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine